Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 69.0% in June

Bone Biologics Co. (NASDAQ:BBLG) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 21,800 shares, an increase of 69.0% from the May 31st total of 12,900 shares. Based on an average daily trading volume, of 79,700 shares, the short-interest ratio is presently 0.3 days. Approximately 4.2% of the shares of the stock are short sold.

Bone Biologics Stock Performance

Shares of NASDAQ BBLG traded up $0.01 during trading hours on Friday, reaching $1.22. 31,940 shares of the stock traded hands, compared to its average volume of 93,317. Bone Biologics has a 52-week low of $1.13 and a 52-week high of $14.16. The company’s 50-day simple moving average is $1.60 and its two-hundred day simple moving average is $2.57.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.60) by $6.29. On average, sell-side analysts anticipate that Bone Biologics will post -5.32 EPS for the current fiscal year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.